Project
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer
Automatically Closed · 2013 until 2019
Weder Patrik, Thürlimann Beat, Ruhstaller Thomas, Maier Reinhard, Riniker Salome, Öhlschlegel Christian, Hasler-Strub Ursula
Type
Range
Units
Status
Start Date
End Date
Financing
Study Design
Brief description/objective
The primary objective of this trial is to evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inbibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) and of a chemotherapy-containing dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) in patients with HER2-positive metastatic breast cancer.